Ballentine Partners LLC Grows Stock Holdings in Takeda Pharmaceutical Co. $TAK

Ballentine Partners LLC lifted its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 25.2% during the second quarter, Holdings Channel reports. The institutional investor owned 48,034 shares of the company’s stock after purchasing an additional 9,656 shares during the period. Ballentine Partners LLC’s holdings in Takeda Pharmaceutical were worth $743,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new position in shares of Takeda Pharmaceutical during the 1st quarter valued at $37,000. Farther Finance Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock valued at $69,000 after buying an additional 1,045 shares in the last quarter. Fifth Third Bancorp lifted its stake in shares of Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock valued at $78,000 after buying an additional 2,411 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after buying an additional 1,296 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Takeda Pharmaceutical in the 1st quarter worth $125,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.6%

Shares of TAK stock opened at $14.74 on Friday. The stock has a market cap of $46.90 billion, a P/E ratio of 49.13 and a beta of 0.22. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.69. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company’s fifty day simple moving average is $14.84 and its two-hundred day simple moving average is $14.84.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research cut shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.